Organicell Regenerative Medicine, Inc.
OTC: OCEL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Harry L. Leider FACPE,
- Employees
- 20
- Headquarters
- Miami, United States
- IPO year
- 2016
- Market cap
- $20.0M
- Website
- https://www.organicell.com
Loading OCEL…
Loading profile data…Frequently asked questions about OCEL
What does Organicell Regenerative Medicine, Inc. (OCEL) do?
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNA...
Where does OCEL trade?
Organicell Regenerative Medicine, Inc. (OCEL) trades on the Other OTC.
What sector is OCEL in?
Organicell Regenerative Medicine, Inc. (OCEL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Organicell Regenerative Medicine, Inc.?
Harry L. Leider FACPE, is the chief executive officer of Organicell Regenerative Medicine, Inc. (OCEL).
Where is Organicell Regenerative Medicine, Inc. headquartered?
Organicell Regenerative Medicine, Inc. is headquartered in United States.
Does OCEL pay a dividend?
Organicell Regenerative Medicine, Inc. (OCEL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OCEL go public?
Organicell Regenerative Medicine, Inc. (OCEL) completed its initial public offering in 2016.